PureTech Health logo

PRTC - PureTech Health Share Price

289.5p 16.5  6.0%

Last Trade - 18/09/20

Mid Cap
Market Cap £826.9m
Enterprise Value £578.7m
Revenue £9.50m
Position in Universe 421st / 1807
Unlock PRTC Revenue
Relative Strength (%)
1m +6.79%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -14.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
2.22 11.8 4.43 2.54 20.7 9.81 15.5 10.00 +34.6%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Puretech Health PLC revenues increased 56% to $6.8M. Net income increased 69% to $124M. Revenues reflect Internal segment increase of 57% to $3.9M, Affiliates segment increase of 74% to $2.9M. Net income benefited from G/L on Invest HFS, Maturi increase from $52.4M to $276.9M (income), Gain/Loss on Derivatives - Hedging increase from $26.3M (expense) to $999K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for PRTC
Graphical History


PRTC Revenue Unlock PRTC Revenue

Net Income

PRTC Net Income Unlock PRTC Revenue

Normalised EPS

PRTC Normalised EPS Unlock PRTC Revenue

PE Ratio Range

PRTC PE Ratio Range Unlock PRTC Revenue

Dividend Yield Range

PRTC Dividend Yield Range Unlock PRTC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
PRTC EPS Forecasts Unlock PRTC Revenue
Profile Summary

PureTech Health PLC is a clinical stage biotechnology company. The Company is engaged in discovering, developing and commercializing medicines for diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders, and inflammatory and immunological diseases, among others. Its segments include Internal and Affiliates. The Internal division is focused on advancing a pipeline fueled by discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. The Affiliates segment is comprised of the programs within its Affiliates division that are consolidated operational subsidiaries that have research and development programs. Its wholly owned pipeline includes various candidates, such as LYT-100, LYT-200, LYT-210, Lymphatic Targeting Chemistry Platform, Milk Exosome Platform and Meningeal Lymphatics Platform.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated May 8, 2015
Public Since June 19, 2015
No. of Shareholders: n/a
No. of Employees: 300
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE All Share , FTSE All Share Health Care , FTSE All Share Pharmaceuticals & Biotechnology , FTSE 350 , FTSE 350 Lower Yield , FTSE 250 , FTSE 350 Pharmaceuticals & Biotechnology ,
Exchange London Stock Exchange (Full)
Shares in Issue 285,647,414
Free Float (0.0%)
Eligible for
PRTC Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for PRTC
Upcoming Events for PRTC
Frequently Asked Questions for PureTech Health
What is the PureTech Health share price?

As of 18/09/20, shares in PureTech Health are trading at 289.5p, giving the company a market capitalisation of £826.9m. This share price information is delayed by 15 minutes.

How has the PureTech Health share price performed this year?

Shares in PureTech Health are currently trading at 289.5p and the price has moved by 1.94% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the PureTech Health price has moved by 21.92% over the past year.

What are the analyst and broker recommendations for PureTech Health?

Of the analysts with advisory recommendations for PureTech Health, there are there are currently 3 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for PureTech Health is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will PureTech Health next release its financial results?

PureTech Health is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the PureTech Health dividend yield?

PureTech Health does not currently pay a dividend.

Does PureTech Health pay a dividend?

PureTech Health does not currently pay a dividend.

When does PureTech Health next pay dividends?

PureTech Health does not currently pay a dividend.

How do I buy PureTech Health shares?

To buy shares in PureTech Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of PureTech Health?

Shares in PureTech Health are currently trading at 289.5p, giving the company a market capitalisation of £826.9m.

Where are PureTech Health shares listed? Where are PureTech Health shares listed?

Here are the trading details for PureTech Health:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: PRTC
What kind of share is PureTech Health?

Based on an overall assessment of its quality, value and momentum, PureTech Health is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a PureTech Health share price forecast 2020?

Shares in PureTech Health are currently priced at 289.5p. At that level they are trading at 66.89% discount to the analyst consensus target price of 874.36.

Analysts covering PureTech Health currently have a consensus Earnings Per Share (EPS) forecast of 0.4 for the next financial year.

How can I tell whether the PureTech Health share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PureTech Health. Over the past six months, the relative strength of its shares against the market has been 6.68%. At the current price of 289.5p, shares in PureTech Health are trading at 6.57% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the PureTech Health PE Ratio?

The PureTech Health PE ratio based on its reported earnings over the past 12 months is 5.72. The shares are currently trading at 289.5p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of PureTech Health?

PureTech Health's management team is headed by:

Daphne Zohar - CEO
Robert Langer - CFD
Marjorie Scardino - NID
Raju Kucherlapati - NID
John Lamattina - NID
Stephen Muniz - COO
Eric Elenko - OTH
Christopher Viehbacher - NEC
Joseph Bolen - CSO
Joep Muijrers - CFO
Bharatt Chowrira - PRE
Who are the major shareholders of PureTech Health?

Here are the top five shareholders of PureTech Health based on the size of their shareholding:

INVESCO Asset Management Limited Investment Advisor/Hedge Fund
Percentage owned: 31.58% (90.2m shares)
Invesco UK Equity High Income Mutual Fund
Percentage owned: 18.38% (52.5m shares)
Baillie Gifford & Co. Investment Advisor
Percentage owned: 9.09% (26.0m shares)
Invesco UK Equity Income Fund UK Mutual Fund
Percentage owned: 8.78% (25.1m shares)
Lansdowne Partners (UK) LLP Investment Advisor/Hedge Fund
Percentage owned: 8.3% (23.7m shares)
Similar to PRTC
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.